Triamcinolone controlled-release - Icon Bioscience

Drug Profile

Triamcinolone controlled-release - Icon Bioscience

Alternative Names: IBI-20089

Latest Information Update: 03 May 2016

Price : $50

At a glance

  • Originator Icon Bioscience
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Diabetic macular oedema
  • No development reported Age-related macular degeneration; Retinal oedema

Most Recent Events

  • 03 May 2016 Phase-I clinical trials in Diabetic macular oedema in USA (Intravitreous)
  • 25 Sep 2015 No recent reports on development identified - Phase-I for Retinal oedema in USA (Intravitreous)
  • 25 Sep 2015 No recent reports on development identified - Phase-I/II for Age-related macular degeneration (Combination therapy) in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top